Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Novo Nordisk and GSK plc announced licensing deals with smaller biotechs. The FDA granted approval to Merck's drug, Welireg, ...

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO ...

Novo Nordisk and Septerna plan to create new obesity pills that target G protein-coupled receptors (GPCRs), including GLP-1, GIP, and glucagon. HealthDay News — Danish drugmaker Novo Nordisk is ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

A key catalyst was Novo Nordisk’s recent $2.2 billion exclusive global collaboration and licensing deal with Septerna for developing and commercializing oral small-molecule medicines for ...

Investors were disappointed when Novo Nordisk A/S (NYSE ... for early-stage candidates like Amycretin and others bought from Septerna and United Laboratories International show the company ...

Novo Nordisk is banking on fresh leadership to ... The company last week announced a licensing deal with the U.S. biotech company Septerna for experimental small-molecule pills for obesity and ...